Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
12 déc. 2024 06h00 HE
|
Keros Therapeutics, Inc.
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq:...
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
09 déc. 2024 19h30 HE
|
Keros Therapeutics, Inc.
Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1...
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
03 déc. 2024 07h00 HE
|
Keros Therapeutics, Inc.
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered...
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
26 nov. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
06 nov. 2024 16h01 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
06 nov. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
05 nov. 2024 09h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
16 oct. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
12 sept. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
03 sept. 2024 08h00 HE
|
Keros Therapeutics, Inc.
LEXINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...